DrugPatentWatch Database Preview

Ubrogepant - Generic Drug Details

« Back to Dashboard

What are the generic sources for ubrogepant and what is the scope of patent protection?

Ubrogepant is the generic ingredient in one branded drug marketed by Allergan and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ubrogepant has eighty-six patent family members in forty countries.

One supplier is listed for this compound.

Summary for ubrogepant

International Patents:	86
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	6
Patent Applications:	38
What excipients (inactive ingredients) are in ubrogepant?	ubrogepant excipients list
DailyMed Link:	ubrogepant at DailyMed

Recent Clinical Trials for ubrogepant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Allergan	Phase 1
Allergan	Phase 3

See all ubrogepant clinical trials

US Patents and Regulatory Information for ubrogepant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No			Y	Y
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No			Y	Y
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes			Y
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No
Allergan	UBRELVY	ubrogepant	TABLET;ORAL	211765-002	Dec 23, 2019		RX	Yes	Yes			Y	Y

International Patents for ubrogepant

Country	Patent Number	Estimated Expiration
Russian Federation	2696578
New Zealand	610468
Serbia	53610
South Korea	101537877
World Intellectual Property Organization (WIPO)	2016105670
European Patent Office	2821407